Cargando…

Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials

BACKGROUND: Erythropoiesis-stimulating agents (ESAs) are the standard treatment for patients with renal anemia to increase hemoglobin (Hb) levels and reduce the need for blood transfusions. However, treatments targeting high Hb levels require high doses of ESAs administered intravenously, which is a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Hiroyasu, Yamada, Takashi, Miyazaki, Ken, Yamashita, Takuto, Kato, Takuya, Ohara, Kenichi, Nakamura, Yusuke, Akizawa, Tadao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Nature Singapore 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352152/ https://www.ncbi.nlm.nih.gov/pubmed/37095342 http://dx.doi.org/10.1007/s10157-023-02353-x

Ejemplares similares

Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis
por: Akizawa, Tadao, et al.
Publicado: (2021)

Molidustat for the treatment of anemia in Japanese patients undergoing peritoneal dialysis: a single‐arm, open‐label, phase 3 study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Molidustat for the treatment of renal anaemia in patients with dialysis-dependent chronic kidney disease: design and rationale of three phase III studies
por: Akizawa, Tadao, et al.
Publicado: (2019)

Molidustat for anemia correction in Japanese patients undergoing hemodialysis: a single‐arm, phase 3 study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies
por: Yamamoto, Hiroyasu, et al.
Publicado: (2019)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
por: Narita, Ichiei, et al.
Publicado: (2022)

Clinical parameters among patients in Japan with anemia and non-dialysis-dependent chronic kidney disease with and without diabetes mellitus who received roxadustat
por: Akizawa, Tadao, et al.
Publicado: (2022)

A Phase 3 Study of Enarodustat in Anemic Patients with CKD not Requiring Dialysis: The SYMPHONY ND Study
por: Akizawa, Tadao, et al.
Publicado: (2021)

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

Absorption, distribution, metabolism and excretion of molidustat in healthy participants
por: Lentini, Silvia, et al.
Publicado: (2020)

Structural Basis of Prolyl Hydroxylase Domain Inhibition by Molidustat
por: Figg, William D., et al.
Publicado: (2021)

Mimicking Hypoxia to Treat Anemia: HIF-Stabilizer BAY 85-3934 (Molidustat) Stimulates Erythropoietin Production without Hypertensive Effects
por: Flamme, Ingo, et al.
Publicado: (2014)

Drug‐drug interaction of atazanavir on UGT1A1‐mediated glucuronidation of molidustat in human
por: van der Mey, Dorina, et al.
Publicado: (2020)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

Clinical significance of parathyroid intervention on CKD-MBD management
por: Ogata, Hiroaki, et al.
Publicado: (2008)

Control of severe hyperparathyroidism in dialysis patients with nodular hyperplasia
por: Fukagawa, Masafumi, et al.
Publicado: (2008)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
por: Akizawa, Tadao, et al.
Publicado: (2019)

Discovery of Molidustat (BAY 85‐3934): A Small‐Molecule Oral HIF‐Prolyl Hydroxylase (HIF‐PH) Inhibitor for the Treatment of Renal Anemia
por: Beck, Hartmut, et al.
Publicado: (2018)

Hyperbaric area index calculated from ABPM elucidates the condition of CKD patients: the CKD-JAC study
por: Iimuro, Satoshi, et al.
Publicado: (2014)

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
por: Larsson, Tobias E., et al.
Publicado: (2017)

The management of anemia in pediatric peritoneal dialysis patients: Guidelines by an ad hoc European committee
por: Schröder, Cornelis H.
Publicado: (2003)

Efficacy and safety of evocalcet in Japanese peritoneal dialysis patients
por: Tsuruya, Kazuhiko, et al.
Publicado: (2019)

Risk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study
por: Inaguma, Daijo, et al.
Publicado: (2016)

Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis
por: Honda, Hirokazu, et al.
Publicado: (2017)

Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2019)

The Influence of Inflammation on Anemia in CKD Patients
por: Gluba-Brzózka, Anna, et al.
Publicado: (2020)

Correction to: Association of adiposity with hemoglobin levels in patients with chronic kidney disease not on dialysis
por: Honda, Hirokazu, et al.
Publicado: (2018)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

Dialysis‐related practice patterns among hemodialysis patients with cancer
por: Nishiwaki, Hiroki, et al.
Publicado: (2018)

A prospective observational study of early intervention with erythropoietin therapy and renal survival in non-dialysis chronic kidney disease patients with anemia: JET-STREAM Study
por: Akizawa, Tadao, et al.
Publicado: (2016)

Treatment of anemia associated with chronic kidney disease with the HIF prolyl hydroxylase inhibitor enarodustat: A review of the evidence
por: Fujikawa, Ryo, et al.
Publicado: (2022)

Psychological Flexibility and Depression in Advanced CKD and Dialysis
por: Iida, Hidekazu, et al.
Publicado: (2020)

Nephrologists’ Perspectives on Gender Disparities in CKD and Dialysis
por: Tong, Allison, et al.
Publicado: (2021)

Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006–2015)
por: Park, Haesuk, et al.
Publicado: (2018)

New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study
por: Minutolo, Roberto, et al.
Publicado: (2022)

Association of coping strategies with mortality and health-related quality of life in hemodialysis patients: The Japan Dialysis Outcomes and Practice Patterns Study
por: Niihata, Kakuya, et al.
Publicado: (2017)

Haemoglobin concentration and survival of haemodialysis patients before and after experiencing cardiovascular disease: a cohort study from Japanese dialysis outcomes and practice pattern study (J-DOPPS)
por: Kido, Ryo, et al.
Publicado: (2019)

Chapter 1: Diagnosis and evaluation of anemia in CKD
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_d1bbi57vmp9e4v7tb9gi1v6bfe